Allogene Therapeutics shared promising Phase 1 results showcasing ALLO-316's potential in advanced renal cell carcinoma patients at SITC and IKCS.

Fate Therapeutics Shares Preclinical Data on FT836, a MICA/B-targeted CAR T-cell, at 2024 SITC Meeting.

Myeloid Therapeutics to Present on MT-303, a Pioneering mRNA CAR Targeting GPC3 in Advanced HCC, at SITC 2024.

OncoResponse Reports Phase 1 Findings of OR502, an anti-LILRB2 Antibody, in Patients with Advanced Cancer.

Harbour BioMed has filed an IND application for HBM9378/SKB378 to treat chronic obstructive pulmonary disease.

SystImmune, Inc. has received FDA approval for the IND application of BL-M17D1 targeting advanced solid tumors.

Nammi Therapeutics, Inc. has reported the first patient has received QXL138AM in a Phase 1 trial focused on advanced solid tumors and multiple myeloma.

Pheast Shares Latest Preclinical Findings on PHST001, an Anti-CD24 Checkpoint Inhibitor for Macrophages, at SITC 2024.

Radella Pharmaceuticals reveals preliminary results from the Phase 1a trial of MD-18, a groundbreaking peptide aimed at PTP1B to combat obesity.

TEZSPIRE achieved its two main goals in the Phase III WAYPOINT study involving patients with chronic rhinosinusitis and nasal polyps.

Palleon Pharmaceuticals shares findings from the Phase 1/2 GLIMMER-01 study on E-602 combined with Cemiplimab for solid tumor patients at the SITC Annual Meeting.

NextCure presents preclinical findings for LNCB74 and new clinical biomarker results for the NC410 combination at the Society for Immunotherapy of Cancer Annual Meeting.